{
    "clinical_study": {
        "@rank": "31869", 
        "arm_group": [
            {
                "arm_group_label": "3 month OCT follow-up, CoCr-EES", 
                "description": "Elective PCI can be performed with the use of an EES. PCI in another vessel or follow-up angiography is expected to be performed 3 months after the index procedure."
            }, 
            {
                "arm_group_label": "1 month OCT follow-up, CoCr-EES", 
                "description": "Elective PCI can be performed with the use of an EES. PCI in another vessel or follow-up angiography is expected to be performed 1 months after the index procedure."
            }
        ], 
        "brief_summary": {
            "textblock": "To treat patients with stable coronary artery disease, elective percutaneous coronary\n      intervention (PCI) will be performed with the use of an everolimus-eluting cobalt- chromium\n      stent (everolimus-eluting stent: EES, Xience Prime, Xpedition), which is the current\n      standard drug-eluting stent (DES). Vascular responses at the site of stent placement will be\n      evaluated by optical coherence tomography (OCT) at 1 or 3 months and at 12 months after\n      stent placement, along with observation of changes over time in the target vessel. The\n      relationships between OCT findings and the time course of platelet aggregation and between\n      OCT findings and the occurrence of major cardio- cerebrovascular events will also be\n      elucidated."
        }, 
        "brief_title": "Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent and Platelet AggregatioN Studies In Patients With Stable Angina Managed as Elective Case", 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients having at least one de novo lesion in a coronary artery in whom PCI with a\n             DES is indicated\n\n          -  Patients aged 20 to less than 85 years at the time of informed consent\n\n          -  Patients who have provided informed consent written by themselves\n\n          -  Patients who are able to undergo OCT examinations of the site of stent placement at 1\n             or 3 months and at 12 months\n\n        Exclusion Criteria:\n\n          -  If it is judged difficult to perform clinical and angiographic follow-up at 12 months\n             (considering the patient's remote place of residence, etc.)\n\n          -  Patients with acute myocardial infarction (AMI)\n\n          -  Patients in a state of shock\n\n          -  Patients with cardiac failure\n\n          -  Patients having a culprit lesion in the left main coronary artery trunk\n\n          -  Patients having a lesion with a reference vessel diameter of less than 2.0 mm or 4.5\n             mm or larger by visual estimate\n\n          -  Patients having an in-stent restenosis lesion as the culprit lesion\n\n          -  Patients having chronic renal failure with a serum creatinine level of 2.0 mg/dL or\n             higher at a screening visit\n\n          -  Patients on hemodialysis\n\n          -  Cancer patients with a life expectancy of less than 2 years\n\n          -  Patients who are scheduled to undergo elective surgery requiring discontinuation of\n             antiplatelet therapy within the next 3 months\n\n          -  Pregnant women or women expected to become pregnant\n\n          -  Patients with a history of adverse reactions to aspirin or clopidogrel (however, it\n             is acceptable to enroll patients in whom the safety of ticlopidine has been\n             confirmed, even if they have a history of adverse reactions to clopidogrel)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "84 Years", 
            "minimum_age": "20 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "primary care clinic"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02014818", 
            "org_study_id": "MECHANISM-Elective"
        }, 
        "intervention": {
            "arm_group_label": [
                "3 month OCT follow-up, CoCr-EES", 
                "1 month OCT follow-up, CoCr-EES"
            ], 
            "intervention_name": "CoCr-EES", 
            "intervention_type": "Device", 
            "other_name": [
                "XIENCE PRIME", 
                "XIENCE Xpedition"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Chromium", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 12, 2013", 
        "location": {
            "contact": {
                "last_name": "Toshiro Shinke"
            }, 
            "facility": {
                "address": {
                    "city": "Kobe", 
                    "country": "Japan", 
                    "zip": "657-850"
                }, 
                "name": "Kobe University Graduate School of Medicine"
            }, 
            "investigator": {
                "last_name": "Toshiro Shinke, Assistant Professor", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "2", 
        "official_title": "Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent and Platelet AggregatioN Studies In Patients With Stable Angina Managed as Elective Case : MECHANISM-Elective", 
        "other_outcome": {
            "description": "(1) at the time of PCI, (2) at the time of OCT at 1 or 3 months after PCI, (3) at 12-month follow-up, and (4) at the time of occurrence of a cardio-cerebrovascular event.", 
            "measure": "Platelet Aggregation Test", 
            "safety_issue": "Yes", 
            "time_frame": "At  the time of OCT follow-up (1 month or 3 month) and 12 month"
        }, 
        "overall_contact": {
            "last_name": "Toshiro Shinke, Assistant Professor", 
            "phone": "+81-78-881-1212"
        }, 
        "overall_official": {
            "affiliation": "Kobe University Graduate School of Medicine", 
            "last_name": "Toshiro Shinke, Assistant Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Rate of stent-strut coverage determined by OCT at 3 months after stent placement (To observe temporal course from the early stage, the rate of stent-strut coverage in the 1-month arm will also be evaluated in a complementary manner, separately from the 3-month arm.) To identify the factors defining the strut coverage at 1-month or 3-months, from OCT index, blood markers, platelet aggregation test immediately after stenting, the strut coverage of 1 to 3 months", 
            "measure": "Rate of stent-strut coverage determined by OCT.", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02014818"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kobe University", 
            "investigator_full_name": "Toshiro Shinke, MD, PhD", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "All-cause Death, Cardiac death, MI, Stroke, Major bleeding", 
                "measure": "All-cause Death, Cardiac death, MI, Stroke, Major bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "1-year"
            }, 
            {
                "measure": "Any TLR", 
                "safety_issue": "No", 
                "time_frame": "1-year"
            }, 
            {
                "measure": "Clinically-driven TLR", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Any TVR", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "CABG", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Any revascularization", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Angiographic binary restenosis", 
                "safety_issue": "No", 
                "time_frame": "12 month"
            }, 
            {
                "description": "All-cause death, Any MI including non-target territory, Any repeat revascularization\n,Stroke", 
                "measure": "Patient-oriented composite", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Determination of factors associated with 12-month rate of stent-strut coverage on the basis of OCT findings, circulating biomarkers, and platelet aggregation test results immediately after stent placement", 
                "measure": "The percentage of stent strut coverage  by OCT", 
                "safety_issue": "Yes", 
                "time_frame": "12 month"
            }, 
            {
                "description": "The percentage of stent strut malapposition\nThe presence of Intra-stent thrombus\nIntra-stent thrombus area (Maximum site)\nIntra-stent thrombus length\nThe number of Intra-stent thrombus", 
                "measure": "OCT endpoint", 
                "safety_issue": "Yes", 
                "time_frame": "1-month or 3-month"
            }, 
            {
                "description": "In-segment late loss\nMinimal lumen diameter (MLD), reference vessel diameter (RVD), percent diameter stenosis (%DS)\nIn-stent late loss\nBinary restenosis (In-stent, In-segment, Peri-stent)\nAngiographically detected stent fracture\uff08based on Popma's classification \uff09", 
                "measure": "Angiographic Quantitative analysis", 
                "safety_issue": "No", 
                "time_frame": "12 month"
            }, 
            {
                "description": "Peri-stent contrast stain (PSS)\nSite and pattern of restenosis (based on Mehran clasification)", 
                "measure": "Angiographic Qualitative analysis", 
                "safety_issue": "Yes", 
                "time_frame": "12 month"
            }
        ], 
        "source": "Kobe University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kobe University", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}